US Drug Prices And R&D, Take 2: A Reply To Grabowski And Manning, And To Light
To answer Health Affairs responses, Peter Bach and Nancy Yu point back to the research, emphasizing the original intent of the conservative R&D cost assumptions.
Originally published on 07/27/2017 in Health Affairs Blog
Health Affairs Blog published two articles in response to Drug Pricing Lab's original research article "R&D costs for pharmaceutical companies do not explain elevated US drug prices." Donald W. Light presents the concern about perpetuating the "foreign free rider myth," the claim that other nations' R&D costs are paid for by the U.S. Grabowski and Manning are concerned for the future of the U.S. market-based system if the U.S. were to adopt international prices. Dr. Peter Bach and Nancy Yu point back to the research, emphasizing that the original intent of the conservative R&D cost assumptions accounted for these concerns.
Read the full text here.